Similar approaches have been used to covalently target the cysteine of KRAS G12C, and two of the resulting drugs, sotorasib and adagrasib, have now been FDA approved for the treatment of patients with advanced NSCLC whose tumors harbor KRAS G12C mutations (18–23). This evidence concerns the gene KRAS and non-small cell lung carcinoma.